Figure 7. Five-year recurrence-free survival rate was 75% in UCSF Out patients exhibiting tumor response to IBT and 85.6% in UCSF In recipients of our trial, but 0% in UCSF Out patients without postinterventional tumor response, respectively (P<0.001).